G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells
TL;DR: Human leukemic HL60 transformant lines constructed in which full length bcl-2 antisense message was conditionally expressed by a tetracycline-regulatable expression system showed that cells died by autophagy, but not by apoptosis.
Book ChapterDOI
Methods for Assessing Autophagy and Autophagic Cell Death
Ezgi Tasdemir,Ezgi Tasdemir,Ezgi Tasdemir,Lorenzo Galluzzi,Lorenzo Galluzzi,Lorenzo Galluzzi,M. Chiara Maiuri,M. Chiara Maiuri,M. Chiara Maiuri,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Ilio Vitale,Ilio Vitale,Ilio Vitale,Emilie Hangen,Emilie Hangen,Emilie Hangen,Nazanine Modjtahedi,Nazanine Modjtahedi,Nazanine Modjtahedi,Guido Kroemer,Guido Kroemer,Guido Kroemer +23 more
TL;DR: This work detail and critically assess a series of methods to promote and inhibit autophagy via pharmacological and genetic manipulations, and describes a strategy for discriminating cell death with autophagic from cell death through autophagosomes.
Journal Article
Potassium Leakage During the Apoptotic Degradation Phase
Bruno Dallaporta,Tamara Hirsch,Santos A. Susin,Naoufal Zamzami,Nathanael Larochette,Catherine Brenner,Isabel Marzo,Guido Kroemer +7 more
TL;DR: Information on the impact of K+ on the apoptotic process in thymocytes and T cell hybridoma cells and the step-wise acquisition of membrane dysfunction in apoptosis indicate an important role for the disruption of normal K+ homeostasis in apoptotic degradation.
Journal ArticleDOI
Bid acts on the permeability transition pore complex to induce apoptosis
Naoufal Zamzami,Chahrazed El Hamel,Carine Maisse,Catherine Brenner,Cristina Muñoz-Pinedo,Cristina Muñoz-Pinedo,Anne-Sophie Belzacq,Paola Costantini,Helena L. A. Vieira,Markus Loeffler,Gérard Molle,Guido Kroemer +11 more
TL;DR: It is shown that Bid-induced MMP can be inhibited, both in cells and in the cell-free system, by three pharmacological inhibitors of the permeability transiton pore complex (PTPC), namely cyclosporin A, N-methyl-4-Val-cyclospor in A, and bongkrekic acid (a ligand of the adenine nucleotide translocase, ANT, one of the PTPC components).
Journal ArticleDOI
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
Erika Vacchelli,Lorenzo Galluzzi,Alexander M.M. Eggermont,Wolf Hervé Fridman,Jérôme Galon,Catherine Sautès-Fridman,Eric Tartour,Laurence Zitvogel,Guido Kroemer +8 more
TL;DR: This Trial Watch will summarize the results of recently completed clinical trials and discuss the progress of ongoing studies that have evaluated/are evaluating FDA-approved TLR agonists as off-label medications for cancer therapy.